Novelos reports encouraging Phase II results of cancer drug

In this trial, 15 patients have now been enrolled and, to date, 60% (nine patients) have had slower than expected disease progression. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies.

Carolyn Krasner, principal investigator of NOV-002, said: “I am encouraged by these results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the treated patients. Most women who have failed three lines of chemotherapy would be expected to progress in about eight weeks.”